IN2014MN01724A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01724A
IN2014MN01724A IN1724MUN2014A IN2014MN01724A IN 2014MN01724 A IN2014MN01724 A IN 2014MN01724A IN 1724MUN2014 A IN1724MUN2014 A IN 1724MUN2014A IN 2014MN01724 A IN2014MN01724 A IN 2014MN01724A
Authority
IN
India
Prior art keywords
immune cell
moiety
further moiety
molecule
unwanted cells
Prior art date
Application number
Other languages
English (en)
Inventor
Mark Cobbold
David Millar
Original Assignee
Univ Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45991852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN01724(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Birmingham filed Critical Univ Birmingham
Publication of IN2014MN01724A publication Critical patent/IN2014MN01724A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN1724MUN2014 2012-02-28 2013-02-28 IN2014MN01724A (OSRAM)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1203442.7A GB201203442D0 (en) 2012-02-28 2012-02-28 Immunotherapeutic molecules and uses
PCT/GB2013/050499 WO2013128194A1 (en) 2012-02-28 2013-02-28 Immunotherapeutic molecules and uses

Publications (1)

Publication Number Publication Date
IN2014MN01724A true IN2014MN01724A (OSRAM) 2015-05-29

Family

ID=45991852

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1724MUN2014 IN2014MN01724A (OSRAM) 2012-02-28 2013-02-28

Country Status (9)

Country Link
US (3) US9822180B2 (OSRAM)
EP (1) EP2819701B2 (OSRAM)
JP (1) JP6273215B2 (OSRAM)
CN (1) CN104321081A (OSRAM)
AU (1) AU2013227477B2 (OSRAM)
CA (1) CA2865482A1 (OSRAM)
GB (1) GB201203442D0 (OSRAM)
IN (1) IN2014MN01724A (OSRAM)
WO (1) WO2013128194A1 (OSRAM)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2686020T3 (en) 2011-03-17 2017-05-01 Univ Birmingham REDIRECTED IMMUNTERY
RU2632647C2 (ru) 2011-04-22 2017-10-06 Аптево Рисерч Энд Девелопмент Ллс Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
EP3677310A1 (en) 2012-10-08 2020-07-08 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
CA2910278C (en) 2013-05-02 2021-09-28 Anaptysbio, Inc. Antibodies directed against programmed death-1 (pd-1)
JP6545666B2 (ja) 2013-05-28 2019-07-17 ディーシービー−ユーエスエー エルエルシーＤｃｂ−Ｕｓａ Ｌｌｃ タンパク質薬物の不活性化のための抗体ロッカー
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
JP6449295B2 (ja) 2013-12-17 2019-01-09 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体および使用方法
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
RU2690670C2 (ru) 2014-03-12 2019-06-05 Ида Рисерч Энд Дивелопмент Ко., Лтд Снижение уровней или активности системных регуляторных т-клеток для лечения заболевания или повреждения цнс
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR20170010863A (ko) 2014-07-01 2017-02-01 화이자 인코포레이티드 이중특이성 이종이량체성 디아바디 및 이의 용도
BR112017001579A2 (pt) * 2014-07-25 2017-11-21 Cytomx Therapeutics Inc anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
US20170247476A1 (en) * 2014-09-25 2017-08-31 Amgen Inc. Protease-activatable bispecific proteins
JP2018508481A (ja) * 2015-02-02 2018-03-29 ザ ユニバーシティ オブ バーミンガム 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体
BR112017019559B1 (pt) * 2015-03-13 2020-08-04 Cytomx Therapeutics, Inc Anticorpos anti-pdl1, anticorpos anti-pdl1 ativáveis, e métodos de uso destes
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HK1252158A1 (zh) * 2015-05-01 2019-05-17 Genentech, Inc. 掩蔽抗cd3抗体和使用方法
EP3296395B2 (en) * 2015-05-13 2024-06-19 Chugai Seiyaku Kabushiki Kaisha Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
KR101997241B1 (ko) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
EP3368077A4 (en) 2015-10-30 2019-10-16 Aleta Biotherapeutics Inc. COMPOSITIONS AND METHODS FOR TUMOR TRANSDUCTION
AU2016343809B2 (en) * 2015-10-30 2022-08-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
EP3377103B2 (en) * 2015-11-19 2025-03-12 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
JP6797203B2 (ja) 2015-12-17 2020-12-09 ザ・ジョンズ・ホプキンス・ユニバーシティー デスレセプターアゴニストによる全身性硬化症の改善
CN108697798A (zh) * 2016-02-16 2018-10-23 达纳-法伯癌症研究所有限公司 免疫疗法组合物及方法
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
EP3426689A4 (en) * 2016-03-08 2020-01-15 Maverick Therapeutics, Inc. INDUCIBLE BINDING PROTEINS AND METHOD FOR USE
BR112018016281A2 (pt) * 2016-03-22 2019-01-02 F. Hoffmann-La Roche Ag molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo
CA3020339C (en) 2016-04-07 2022-05-03 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
BR112018073761A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteínas de ligação ao cd3 de fragmento variável de cadeia única
CN119060177A (zh) 2016-05-20 2024-12-03 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR102531889B1 (ko) * 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
WO2018085468A1 (en) 2016-11-01 2018-05-11 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
JP2020503260A (ja) 2016-11-15 2020-01-30 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
CA3044659A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
KR102630923B1 (ko) * 2016-11-28 2024-01-30 추가이 세이야쿠 가부시키가이샤 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
TWI776827B (zh) 2016-11-28 2022-09-11 日商中外製藥股份有限公司 能夠調節配體結合活性的配體結合分子
SG11201903785TA (en) 2016-12-09 2019-05-30 Seattle Genetics Inc Bivalent antibodies masked by coiled coils
EP3565844B8 (en) 2017-01-09 2023-04-12 Tesaro, Inc. Methods of treating cancer with anti-pd-1 antibodies
EP3579848B1 (en) 2017-02-08 2024-10-30 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
AU2018220736B2 (en) 2017-02-20 2024-10-24 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
BR112019017403A2 (pt) * 2017-02-22 2020-04-14 Aleta Biotherapeutics Inc composições e métodos para o tratamento de câncer
WO2018160754A2 (en) * 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN110770255B (zh) * 2017-04-11 2025-07-01 因荷布瑞克斯生物科学公司 具有受限cd3结合的多特异性多肽构建体及其使用方法
WO2018204717A1 (en) * 2017-05-03 2018-11-08 Harpoon Therapeutics, Inc. Compositions and methods for adoptive cell therapies
KR20200026810A (ko) 2017-05-12 2020-03-11 하푼 테라퓨틱스, 인크. Msln 표적화 삼중 특이적 단백질 및 사용 방법
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
AU2018278327B2 (en) 2017-06-01 2023-03-16 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies and methods of use thereof
IL302614B2 (en) 2017-09-08 2025-04-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
TWI850203B (zh) 2017-10-14 2024-08-01 美商Ｃｙｔｏｍｘ生物製藥公司 抗體、可活化之抗體、雙特異性抗體、和雙特異性可活化之抗體、及其使用方法
WO2019107384A1 (ja) 2017-11-28 2019-06-06 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
WO2019107380A1 (ja) 2017-11-28 2019-06-06 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
WO2019113385A1 (en) * 2017-12-07 2019-06-13 Janux Therapeutics, Inc. Modified t cell receptors
AU2018385756B2 (en) 2017-12-15 2025-10-09 Aleta Biotherapeutics Inc. CD19 variants
WO2019148445A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019157366A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
PE20210375A1 (es) 2018-02-08 2021-03-02 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
US11866498B2 (en) 2018-02-08 2024-01-09 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
JP7515412B2 (ja) * 2018-03-09 2024-07-12 アスクジーン・ファーマ・インコーポレイテッド 新規のサイトカインプロドラッグ
CN112218686A (zh) 2018-04-11 2021-01-12 印希比股份有限公司 具有受限cd3结合的多特异性多肽构建体以及相关方法和用途
KR20210018275A (ko) * 2018-05-07 2021-02-17 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
CN119192397A (zh) 2018-05-14 2024-12-27 哈普恩治疗公司 用于条件性激活免疫球蛋白分子的结合部分
US20210155701A1 (en) * 2018-05-30 2021-05-27 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising il-1r1 binding domain and carrying moiety
US20210253672A1 (en) 2018-05-30 2021-08-19 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule containing single domain antibody
US12077577B2 (en) 2018-05-30 2024-09-03 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
CA3104185A1 (en) * 2018-07-02 2020-01-09 The General Hospital Corporation Antibody tumor-targeting assembly complexes
US12195533B2 (en) 2018-07-24 2025-01-14 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
KR20210043602A (ko) 2018-08-08 2021-04-21 드래곤플라이 쎄라퓨틱스, 인크. Bcma, nkg2d 및 cd16에 결합하는 다중특이성 결합 단백질 및 이의 사용 방법
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
JP7482363B2 (ja) 2018-08-08 2024-05-14 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
JP7557465B2 (ja) * 2018-12-14 2024-09-27 プロヴィヴァ セラピューティクス （ホン コン） リミテッド Ｉｌ－１５組成物およびその使用方法
US11702482B2 (en) * 2018-12-17 2023-07-18 Revitope Limited Twin immune cell engager
CN114390938B (zh) 2019-03-05 2025-03-21 武田药品工业有限公司 受约束的条件性活化的结合蛋白
WO2020214690A1 (en) * 2019-04-15 2020-10-22 Qwixel Therapeutics Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
JP2022530685A (ja) * 2019-05-02 2022-06-30 ザ ジェネラル ホスピタル コーポレイション Ｔｅａｃおよびａｔｔａｃ腫瘍免疫学的組成物および方法
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
WO2020246563A1 (ja) 2019-06-05 2020-12-10 中外製薬株式会社 抗体切断部位結合分子
CN114867494B9 (zh) 2019-12-13 2024-01-12 基因泰克公司 抗ly6g6d抗体及使用方法
JP7483896B2 (ja) * 2020-01-17 2024-05-15 エショー バイオセラピー， インク． オフターゲット毒性を低下させるプロ抗体
CN114945597A (zh) * 2020-01-17 2022-08-26 艾提欧生物疗法有限公司 降低脱靶毒性的前抗体
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
KR20220166814A (ko) 2020-04-09 2022-12-19 싸이톰스 테라퓨틱스, 인크. 활성화 가능한 항체를 함유하는 조성물
IL297412A (en) 2020-05-04 2022-12-01 Immunorizon Ltd Precursor tri-specific antibody constructs and methods of use thereof
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
BR112022024469A2 (pt) 2020-06-19 2023-01-17 Hoffmann La Roche Molécula biespecífica de ativação de células t ativáveis por protease, polipeptídeo específico de idiotipo, composição farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, método para produzir uma molécula biespecífica de ativação de células t ativáveis por protease, molécula biespecífica de ativação de células t ativáveis por protease, uso da molécula biespecífica de ativação de células t ativáveis por protease e método para tratar uma doença em um indivíduo
JP2023531067A (ja) 2020-06-25 2023-07-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子
US20230321239A1 (en) 2020-08-14 2023-10-12 H. Lee Moffitt Cancer Center And Research Institute Inc. Chimeric antigen receptor t cells for treating autoimmunity
MX2023005132A (es) 2020-11-04 2023-05-25 Genentech Inc Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3.
KR20230113581A (ko) 2020-11-25 2023-07-31 실리오 디벨럽먼트, 인크. 종양 특이적 절단성 링커
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CA3201621A1 (en) 2020-12-03 2022-06-09 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
JP2023552812A (ja) 2020-12-09 2023-12-19 ジャナックス セラピューティクス，インク． Ｐｓｍａおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
IL308417A (en) 2021-05-14 2024-01-01 Genentech Inc Methods for the treatment of CD20-positive proliferative disorder with musuntozumab and folatuzumab and dotin
JP2024527401A (ja) * 2021-07-13 2024-07-24 サイノマブ バイオサイエンス リミテッド 神経学的疾患を処置する方法
AR128876A1 (es) 2022-03-28 2024-06-19 Hoffmann La Roche Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
EP4503923A1 (en) 2022-04-04 2025-02-12 The Regents of the University of California Genetic complementation compositions and methods
KR20250004727A (ko) 2022-04-13 2025-01-08 제넨테크, 인크. 모수네투주맙의 약학적 조성물 및 사용 방법
CN119948060A (zh) 2022-09-28 2025-05-06 豪夫迈·罗氏有限公司 改善的蛋白酶可活化的t细胞双特异性抗体
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3578568A (en) 1968-11-29 1971-05-11 Atlantic Richfield Co Purification of low molecular weight epoxides by extractive distillation with a glycol or glycol ether
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0659438A1 (en) 1993-12-23 1995-06-28 Boehringer Mannheim Gmbh Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
JP4212111B2 (ja) * 1995-05-03 2009-01-21 バイオエンハンスメンツ リミテッド 結合能力が光開裂性分子により可逆的に阻害される二重特異性抗体
US20040197336A1 (en) 1995-05-03 2004-10-07 Self Colin Henry Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety
WO1997023237A1 (en) 1995-12-22 1997-07-03 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
CA2265476A1 (en) 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
GB9624993D0 (en) 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy
US7541034B1 (en) 1997-03-20 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
WO1999002175A1 (en) 1997-07-10 1999-01-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
PL199747B1 (pl) † 1998-04-21 2008-10-31 Micromet Ag Jednołańcuchowy wielofunkcyjny polipeptyd, polinukleotyd, wektor, komórka, sposób wytwarzania polipeptydu, kompozycja, zastosowanie polipeptydu lub wektora lub polinukleotydu i zastosowanie polinukleotydu lub wektora oraz sposób identyfikacji aktywatorów lub inhibitorów aktywacji lub stymulacji komórek T
EP1100830B1 (en) 1998-07-28 2003-10-01 Micromet AG Heterominibodies
AU3633000A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
AU2002223350A1 (en) 2000-12-01 2002-06-11 Eleanor N. Fish Cytokine receptor binding peptides
CA2461351C (en) 2001-09-26 2014-08-05 Ira H. Pastan Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
NZ533226A (en) 2001-11-30 2006-05-26 Crucell Holland B Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
EP1519959B1 (en) 2002-02-14 2014-04-02 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
CA2504818C (en) 2002-11-07 2013-04-23 Immunogen, Inc. Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
AU2004210088A1 (en) 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring T cell response
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
ATE493441T1 (de) * 2003-10-16 2011-01-15 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
WO2005052004A2 (en) 2003-11-28 2005-06-09 Micromet Ag Compositions comprising polypeptides
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
GB0404187D0 (en) 2004-02-25 2004-03-31 Biotransformations Ltd Binding agents
US20060045881A1 (en) 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
GT200500255A (es) 2004-09-10 2006-04-10 Anticuerpos anti-5ta humanizados y conjugados anticuerpo anti-5ta/calicheamicina
ATE530198T1 (de) 2005-02-16 2011-11-15 Univ Zuerich Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt ist
US20090238822A1 (en) 2005-10-13 2009-09-24 Virexx Medical Corp. Chimeric Hepatitis C Virus Antigens For Eliciting an Immune Response
US20100184651A1 (en) 2005-11-18 2010-07-22 Dabur Pharma Limited Targeted fusion proteins for cancer therapy
GB0605702D0 (en) 2006-03-21 2006-05-03 Biotransformations Ltd Materials and methods for immune cell stimulation
WO2008019366A2 (en) 2006-08-07 2008-02-14 Ludwig Institute For Cancer Research Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens
US20100215670A1 (en) 2006-10-30 2010-08-26 Jeannick Cizeau Immunotoxin Fusions Comprising An Antibody Fragment and a Plant Toxin Linked by Protease Cleavable Linkers
WO2008063113A1 (en) 2006-11-20 2008-05-29 Cepep Iii Ab Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf
CN101687912B (zh) 2007-01-30 2014-01-22 埃皮瓦克斯公司 调节性t细胞表位、组合物及其用途
AU2008214032B2 (en) 2007-02-02 2012-06-28 Baylor Research Institute Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
GB0716160D0 (en) 2007-08-17 2007-09-26 Biotransformations Ltd Materials and methods for treating cancers which express folate receptors
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
PL2352763T5 (pl) 2008-10-01 2023-01-30 Amgen Research (Munich) Gmbh Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej
US20100189727A1 (en) † 2008-12-08 2010-07-29 Tegopharm Corporation Masking Ligands For Reversible Inhibition Of Multivalent Compounds
US20110178279A1 (en) * 2009-08-03 2011-07-21 Williams John C Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
EP2385955B1 (en) 2009-01-12 2020-08-12 CytomX Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof
CN102770457A (zh) 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
CN102573902A (zh) 2009-11-05 2012-07-11 分子医学和免疫学中心 用于基于亚单位的痘病毒疫苗的包含痘病毒衍生肽和针对抗原呈递细胞的抗体的免疫偶联物
US9193791B2 (en) 2010-08-03 2015-11-24 City Of Hope Development of masked therapeutic antibodies to limit off-target effects
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
MX340556B (es) 2010-08-24 2016-07-14 Roche Glycart Ag Anticuerpos biespecificos activables.
DK2686020T3 (en) 2011-03-17 2017-05-01 Univ Birmingham REDIRECTED IMMUNTERY
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013139789A1 (en) 2012-03-19 2013-09-26 Deutsches Krebsforschungszentrum B-cell receptor complex binding proteins containing t-cell epitopes
HK1204581A1 (en) 2012-04-27 2015-11-27 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US9856314B2 (en) 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
US9127053B2 (en) 2012-06-22 2015-09-08 Cytomx Therapeutics, Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
WO2014052462A2 (en) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
CN105008918A (zh) 2013-01-04 2015-10-28 西托姆克斯治疗公司 用于检测生物系统中的蛋白酶活性的组合物和方法
WO2014144689A1 (en) 2013-03-15 2014-09-18 Bayer Healthcare Llc Pro-drug antibodies against tissue factor pathway inhibitor
AU2014274982B2 (en) 2013-06-04 2019-12-05 Cytomx Therapeutics, Inc Compositions and methods for conjugating activatable antibodies
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
AU2014324884B2 (en) 2013-09-25 2020-03-26 Cytomx Therapeutics, Inc Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US9562073B2 (en) 2014-01-31 2017-02-07 Cytomx Therapeutics, Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
BR112017001579A2 (pt) 2014-07-25 2017-11-21 Cytomx Therapeutics Inc anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos

Also Published As

Publication number Publication date
AU2013227477B2 (en) 2017-03-23
US9822180B2 (en) 2017-11-21
JP2015509952A (ja) 2015-04-02
US20160039942A1 (en) 2016-02-11
EP2819701B1 (en) 2018-07-25
JP6273215B2 (ja) 2018-01-31
CA2865482A1 (en) 2013-09-06
US20180105599A1 (en) 2018-04-19
US20150183875A1 (en) 2015-07-02
US9650445B2 (en) 2017-05-16
CN104321081A (zh) 2015-01-28
EP2819701A1 (en) 2015-01-07
EP2819701B2 (en) 2021-06-02
US10106621B2 (en) 2018-10-23
WO2013128194A1 (en) 2013-09-06
GB201203442D0 (en) 2012-04-11
AU2013227477A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
IN2014MN01724A (OSRAM)
IN2014DN06104A (OSRAM)
MY185016A (en) Progenitor cells of mesodermal lineage
IN2015DN00143A (OSRAM)
EP4582090A3 (en) Composition comprising pegylated arginine deiminase
AU2012335543A8 (en) HER3 antibodies and uses thereof
AU334338S (en) Electronic housing portion
AU334340S (en) Electronic housing portion
AU334280S (en) Electronic housing portion
AU348733S (en) Carburetor main body
AU339157S (en) Carburettor
AU341122S (en) Intake manifold
IN2015DN03795A (OSRAM)
IN2015DN00636A (OSRAM)
AU341133S (en) Carburetor main body
TWD163155S (zh) 耳機
IN2014DN08721A (OSRAM)
AU334281S (en) Electronic housing portion
EP4458361A3 (en) Modulation of ube3a-ats expression
PH12015501083A1 (en) Novel pyridine derivatives
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MY168166A (en) Polymer and Composition Including Same, and Adhesive Composition
AU342351S (en) Automobile
NZ627480A (en) Inhibitors of iap
IN2014KN02745A (OSRAM)